Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy

Executive Summary

The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.

Advertisement

Related Content

Bristol’s Oncology Strategy: Stay In The Lead On Immunotherapy
ASCO Preview: Elotuzumab’s ‘Double Whammy’ Mechanism Hits Hard In Myeloma
Big Market, Broad Plan: Bristol Shares Vision For Opdivo In Lung Cancer
Chugai’s Pockets Are Getting Heavy, So What Next?
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
AstraZeneca/MedImmune Synergies An Advantage In Immune-Mediated Cancer Therapies
Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel